Immunogenicity Risk Assessment of Process-Related Impurities in An Engineered T Cell Receptor Cellular Product

Johanna Mora(Bristol-Myers Squibb (United States)), Chloé Ackaert(Exelis (United States)), Akshata Ijantkar(Bristol-Myers Squibb (Germany)), Vibha Jawa(Bristol-Myers Squibb (Germany)), Caryn Picarillo(Bristol-Myers Squibb (Germany)), Juliette Lamy, Kyle L. Kolaja(Bristol-Myers Squibb (Germany)), Jana Schockaert, Sofie Denies, Yue Hai(Chinese Academy of Sciences), Daron Forman(Bristol-Myers Squibb (Germany)), Jennifer Hu(Massachusetts Institute of Technology), Jochem Gokemeijer(Bristol-Myers Squibb (Germany))
Journal of Pharmaceutical Sciences
May 18, 2024
10.1016/j.xphs.2024.05.018
Cited by 3

Related Papers

Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
|Molecular Therapy — Methods & Clinical Development|2022|113
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene &amp; Cell Therapy and Vaccine Assays)
|Bioanalysis|2021|60
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays
|mAbs|2021|57
2018 White Paper on Recent Issues in Bioanalysis: Focus on Flow Cytometry, Gene Therapy, Cut Points and Key Clarifications on Bav (Part 3 – Lba/Cell-Based Assays: Immunogenicity, Biomarkers and Pk Assays)
|Bioanalysis|2018|53
Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays
|The AAPS Journal|2021|52